Psoriasis Clinical Trial
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
Summary
This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.
Eligibility Criteria
Inclusion Criteria:
Participant has a diagnosis of plaque-type psoriasis up to 20% of body surface area (BSA) involved excluding the scalp, with a Global Severity Score of at least 3 (moderate) at Screening
Participant presents with a representative target lesion that is at least 16 cm² in area, is located on the non-bony areas of the skin, has a Scaling Score up to 2 (moderate), has a DSS of at least 4
Exclusion Criteria:
Other type of psoriasis (other than plaque)
Significant abnormal lab findings
Hypercalcemia
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Fridley Minnesota, 55432, United States
Nashville Tennessee, 37215, United States
Edmonton Alberta, T5K1X, Canada
Barrie Ontario, L4M6L, Canada
North Bay Ontario, P1B3Z, Canada
Waterloo Ontario, N2J1C, Canada
How clear is this clinincal trial information?
